RxDoctor Payments Data

Anna Nikachina, MD

Physical Medicine & Rehabilitation · Redlands, CANPI 1811284102

Payments from drug & device makers

$6,238in general payments, 2019–2025

Across 80 payments — averaging $77.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Curonix LLC$2K
  • SPR Therapeutics, Inc$491
  • Nevro Corp.$196
  • AbbVie$110
  • Painteq LLC$108
  • plus $144 from 5 others

What the payments were for

  • Travel & lodging$4,01364%
  • Food & beverage$2,21035%
  • Education$150%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific45$3,683
Curonix LLC13$1,505
SPR Therapeutics, Inc6$491
Nevro Corp.1$196
AbbVie5$110
Painteq LLC1$108
Valinor Pharma, LLC4$64
Ziehm-orthoscan, Inc.(2 entities)2$33
Scilex Pharmaceuticals Inc.1$18
Fidia Pharma USA Inc.1$14
Collegium Pharmaceutical, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,238 in reported general payments places this provider in the 90th percentile of 830 physical medicine & rehabilitation providers in California.

See all physical medicine & rehabilitation providers in California

Medicare billing

Part B allowed, 2024
$88,663
Medicare patients
230
Services billed
5,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe12$8,675
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen329$8,173
BelbucaBuprenorphine Hcl13$7,296
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen125$3,352
Gabapentin222$2,778
Lidocaine33$2,670
Oxycodone Hcl67$2,021
Morphine Sulfate ErMorphine Sulfate67$1,443
Diclofenac Sodium106$1,425
Pregabalin58$902
Baclofen51$664
Ibuprofen59$489
Tizanidine Hcl35$484
Lidocaine-PrilocaineLidocaine/Prilocaine17$450
Acetaminophen-CodeineAcetaminophen With Codeine28$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$14$7,29613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 830 physical medicine & rehabilitation providers in California.

Other physical medicine & rehabilitation in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →